Since Fra-1 regulates the expression of many genes involved in tumor invasion, especially MMP-1 expression in breast [31], osteosarcoma [32], and colon cancers [33], targeting Fra-1 seems to be a promising strategy for treatment of mCRC. This evidence concerns the gene FOSL1 and neoplasm.